Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01611662 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer
A Phase 2 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT01611662 is a Phase 2 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 32 participants.
The verdict
NCT01611662, a Phase 2 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out what effects, good and/or bad, dose-dense (every 14 days) chemotherapy with gemcitabine (gemcitabine hydrochloride) and cisplatin given before surgery have on patients and their muscle invasive bladder cancer.
Interventions
- OTHER laboratory biomarker analysis
- DRUG cisplatin
- PROCEDURE therapeutic conventional surgery
- DRUG gemcitabine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2012-05-29 |
| Est. Completion | 2019-01-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01611662
The ClinicalTrials.gov registry entry for NCT01611662 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01611662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01611662 about?
NCT01611662 is a clinical study titled "Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer". The purpose of this research study is to find out what effects, good and/or bad, dose-dense (every 14 days) chemotherapy with gemcitabine (gemcitabine hydrochloride) and cisplatin given before surgery have on patients and their muscle invasive bladder cancer.
What is the current status of trial NCT01611662?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2012-05-29. Estimated completion is 2019-01-22.
What interventions are being tested in trial NCT01611662?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cisplatin (DRUG), therapeutic conventional surgery (PROCEDURE), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01611662?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.